InvestorsHub Logo
icon url

oh not again

07/12/12 10:15 PM

#30097 RE: cheyenne1 #30096

well..my opinion is that as I have mentioned before the only chance we have is if Howard teams up with a pharmaceutical company AND that company provides space in their FDA ISO certified facility and assists with FUNDING to PURCHASE any specialzed equipment to MANUFACTURE Aquaprin in quantities SUFFICENT for CLAIMS TESTING. BLOWING MONEY on RENTING buildings and saying that he cannot show people who he can document are significant share holders around is a bunch of horse poop!!! Sorry but thats DA FACTS!!!! ONA

PS OBTW If Howard succedes in doing what I just mentioned we will have something here.... otherwise IMHO we are screwed!!!!!!
icon url

TheFinalCD

07/26/12 1:36 PM

#30156 RE: cheyenne1 #30096

Howard Phykitt commented:

"The first phase of money has been raised, enabling us to produce the product, but only in the area of a few million dollars a year in sales...

I've got this product perfected now. It is fully developed... There is no potassium-based aspirin in the world. There are sodium-based ones and calcium-based ones in Europe, which are very successful products."

An earlier version of Aquaprin (protected with three patents) was not a success after being marketed through a national broker network in the US. The new version, perfected in late 2007, will be sold in small foil packets containing a single granular dose for mixing with water. The facility will employ 25 personnel in the first year of production and will then expand into a new 100,000ft² plant on the same site in phase two when there will be an additional 150 personnel employed. Personnel are being trained at Nash Community College and production personnel are expected to be hired within 12 months.

The Aquaprin product will be in stores for sale in around 15 months (by November 2009). Aquaprin will be manufactured in accordance with the current FDA Analgesics Monograph in the 'permitted combinations' section of the Federal Register and in the USP under the 'Effervescent Aspirin' monograph.